BPC-157 vs TB-500: How the Two Recovery Peptides Differ on the Evidence

BPC-157 and TB-500 are both unapproved synthetic peptides marketed for recovery, but they come from different places. BPC-157 is a 15-amino-acid sequence derived from a protein described in gastric juice. TB-500 is a short, acetylated fragment of thymosin beta-4, a protein involved in organising the cell’s internal scaffolding. Almost all evidence for either comes from animal and cell studies.

They are often sold together, sometimes as a pre-mixed vial, and in July 2026 both went before the same FDA advisory committee. That shared history makes them easy to confuse. The chemistry, the research base and the anti-doping rules are not the same.

This page sets out what each molecule is, what the studies do and do not show, where they stand legally as of September 2026, and what a certificate of analysis (COA) should prove. It contains no dosing or usage guidance.

At a glance

Property	BPC-157	TB-500
What it is	Synthetic 15-amino-acid peptide	Acetylated 7-amino-acid fragment (Ac-LKKTETQ)
Parent molecule	A protein described in human gastric juice	Thymosin beta-4, an actin-binding protein
Main research areas	Gut lining, tendon, ligament, muscle and bone models	Wound and tissue repair, largely borrowed from full-length thymosin beta-4 work
Human evidence	One uncontrolled chart review, one two-person safety pilot	No human exposure data identified by FDA
FDA approval	Not approved	Not approved
July 2026 FDA panel vote	8-6 in favour of compounding list (1 abstention)	8-6 in favour of compounding list (1 abstention)
WADA 2026	Prohibited at all times (S0, named)	Prohibited at all times (S2, thymosin beta-4 derivatives)
Canada	Named in Health Canada’s April 2026 advisory	Named in the same advisory
Extra COA check	Identity by mass spectrometry	Confirm fragment or full-length sequence

What BPC-157 and TB-500 actually are

BPC-157 stands for body protection compound 157. It is a synthetic chain of 15 amino acids whose sequence was taken from a protein reported in human gastric juice. Preclinical work suggests it affects growth hormone receptor expression, pathways involved in blood vessel growth, and inflammatory signalling.¹ In animal data it is broken down quickly, with a reported half-life of under 30 minutes, metabolised in the liver and cleared by the kidneys.¹

TB-500 is not a natural protein. Analysis of a product sold under that name found the N-terminal acetylated 17-23 fragment of human thymosin beta-4, a seven-amino-acid sequence written as Ac-LKKTETQ.⁴ Thymosin beta-4 itself is a much larger, naturally occurring protein that binds actin and has been studied for tissue repair.⁵

One distinction matters more than any other. Sellers often describe TB-500 as if it were thymosin beta-4. It is a fragment of it, and research on the full protein cannot simply be transferred to the fragment. Our glossary entries on BPC-157 and TB-500 cover the terminology in more detail.

How the reported effects differ in practice

In animal models, BPC-157 has been reported to improve functional, structural and biomechanical outcomes after muscle, tendon, ligament and bone injuries.¹ It was first studied for protecting the stomach and gut lining, and that gastrointestinal angle is why it was nominated to FDA for ulcerative colitis.⁸ A large share of the published animal work comes from one Croatian research group, so independent replication remains an open question.

TB-500 claims mostly lean on research into full-length thymosin beta-4, which has been examined in wound, eye and heart models and in small early-phase trials of the whole protein.⁵ FDA’s review of the fragment itself found no human exposure data.⁷ In other words, the popular story that TB-500 works throughout the body while BPC-157 works locally is a marketing framing, not a finding from comparative studies.

The same gap shows up in how each is sold. BPC-157 is often positioned around the gut and specific injured tissues, TB-500 around flexibility and general repair. Those positions trace back to the animal models each was studied in, not to human outcome data, and sellers rarely say so.

No study has compared the two head to head in animals or people. User reports online are plentiful, but they are uncontrolled, often come from people using several substances at once, and cannot separate a peptide effect from rest, physiotherapy, time or expectation.

Evidence quality: how little human data exists

A 2025 systematic review of BPC-157 in orthopaedic sports medicine screened 544 records and included 36 studies. Thirty-five were preclinical and one was clinical.¹ The authors rated the body of evidence as level IV and V and found no clinical safety data.¹

That single clinical study was a retrospective chart review at one Florida clinic. Of 16 patients contacted by phone, 12 had received BPC-157 alone into the knee and most reported less pain. There was no control group and no standardised outcome measure.² A separate 2025 pilot gave intravenous BPC-157 to two adults and reported no measurable changes in routine blood markers.³ Two people cannot establish safety.

Evidence type	BPC-157	TB-500 (fragment)
Cell and animal studies	Dozens, mostly one group	Few; most cited work is on full-length thymosin beta-4
Randomised human trials	None published	None published
Uncontrolled human reports	One chart review, one two-person pilot	None for the fragment
Head-to-head comparison	None	None

There are also structural reasons to be cautious. Small, uncontrolled clinic reports tend to overstate benefit because patients who felt better are easier to reach and more willing to answer. Animal injury models use controlled wounds in young, healthy animals, which is not how tendon or joint problems develop in people. And exposure in a research animal does not translate simply into a human equivalent.

Put plainly, neither peptide has the kind of evidence needed to say what it does in humans, at what exposure, or with what risks.

Safety, side effects and drug testing

Because human data are so thin, the honest answer on side effects is that they are largely unknown. FDA’s review flagged immunogenicity (the risk of an immune reaction to the peptide or its impurities) and peptide-related impurities for BPC-157, stating it lacks sufficient information to know whether the drug would cause harm in humans. For TB-500 it raised aggregation-related immunogenicity and found no human exposure data.⁷

Both molecules are discussed in the literature for promoting blood vessel growth in preclinical models.¹⁵ Researchers raise this as a theoretical concern for anyone with a current or past cancer, but there are no human data either way. Interactions with prescription medicines have not been studied. Health Canada’s 2026 advisory lists infection, allergic reactions, wrong dosing, undeclared ingredients and contaminants such as bacteria and heavy metals among the risks of unauthorised injectable peptides.¹¹ We cover reported problems in more depth in our BPC-157 side effects and safety guide.

For athletes the position is clear. WADA’s 2026 list names BPC-157 under S0 (non-approved substances) and lists thymosin beta-4 and its derivatives, such as TB-500, under S2. Both are prohibited at all times.¹² Anti-doping laboratories have published methods for detecting both.⁴⁶ Routine workplace drug panels are built around drugs such as opioids, cannabis and stimulants rather than peptides.

Legal status in September 2026

United States. Neither peptide is an FDA-approved drug. Both had been in Category 2 of FDA’s interim bulks policy, the group of substances flagged for significant safety risks. In April 2026 FDA moved them out of Category 2 after the original nominations were withdrawn.⁷⁹ On 23 July 2026 the Pharmacy Compounding Advisory Committee voted 8-6, with one abstention, to recommend adding each to the 503A bulks list, over the objections of FDA staff, who pointed to a general lack of quality human data.⁸⁹ We explain that meeting in BPC-157 in 2026: the FDA advisory vote.

The votes are advisory. FDA still has to run notice-and-comment rulemaking before either substance is formally listed, which could take until 2027 or longer.⁹ Until then, a favourable vote is not the same as lawful compounding, and it has no bearing on products sold online as chemicals. Our 503A bulks list explainer walks through each step. State pharmacy boards also set their own rules for compounders.

UK. Neither is a licensed medicine, so neither can lawfully be sold as one. Canada. Health Canada’s April 2026 advisory named BPC-157 and TB-500 among unauthorised injectable peptides it had seized.¹¹

Research use only labels and what a COA should show

Most BPC-157 and TB-500 is sold online as research use only. Regulators do not treat that wording as a shield. In a March 2026 warning letter, FDA said that despite research use only and not for human consumption labels, evidence from the seller’s website showed the products were intended as drugs for human use.¹⁰ Health Canada says the same labelling does not make products legal or exempt.¹¹ Our guide to what research use only means covers the loophole in detail.

A COA only helps if it is specific and checkable. At a minimum it should show:

• HPLC purity, with the chromatogram, not just a percentage.
• Identity by mass spectrometry, with the measured mass matching the expected molecule.
• The exact sequence. For TB-500, the report should say whether the vial holds the Ac-LKKTETQ fragment or full-length thymosin beta-4.⁴
• Endotoxin results, since bacterial toxins survive filtration and are not removed by sterile-looking packaging.
• Sterility testing for anything sold in a vial.
• A lot number matching the vial, the testing laboratory’s name, and a recent date. Blends need results for each component.

Even a genuine COA describes one batch on one day. It is worth contacting the laboratory named on the report to confirm it issued that certificate for that lot.

Frequently asked questions

Is BPC-157 or TB-500 better for recovery?

There is no way to answer that on current evidence. No study has compared them, BPC-157’s human data amount to one uncontrolled chart review and a two-person pilot, and FDA found no human exposure data for the TB-500 fragment.¹⁷ Claims that one is better for tendons and the other for whole-body repair come from marketing and animal extrapolation, not comparative research.

Can you take BPC-157 and TB-500 together?

Blends are widely marketed, but no controlled human study has tested the combination. The only human report we found involving both was a retrospective knee pain chart review in which four patients received BPC-157 with thymosin beta-4, without a control group.² Combining two poorly characterised products also doubles the purity and contamination questions. We do not give usage guidance.

Is BPC-157 legal in the US in 2026?

BPC-157 is not an FDA-approved drug. In July 2026 an FDA advisory committee voted 8-6 to recommend adding it to the list of substances compounding pharmacies may use, but the vote is not binding and FDA must still complete rulemaking.⁹ Selling it online as research use only does not make it lawful for human use.

Is TB-500 banned in sport?

Yes. WADA’s 2026 Prohibited List covers thymosin beta-4 and its derivatives, naming TB-500, under S2, and names BPC-157 under S0. Both are banned in and out of competition.¹² Anti-doping laboratories have published detection methods for both, so athletes subject to testing should assume use can be detected.⁴⁶

Does BPC-157 show up on a drug test?

Not on a routine workplace panel, which looks for drugs such as opioids, cannabis and stimulants. Sports testing is different. Anti-doping laboratories have described methods for identifying BPC-157 and its breakdown products, and a method for detecting the TB-500 fragment in plasma and urine has also been described.⁶⁴ Because both are prohibited at all times under the WADA code, a tested athlete should assume either could be found.

Is TB-500 the same as thymosin beta-4?

No. Thymosin beta-4 is a larger natural protein. A product sold as TB-500 was found to contain a seven-amino-acid acetylated fragment of it, Ac-LKKTETQ.⁴ Some sellers use the two names loosely, which is why a COA should state the sequence and show mass spectrometry results confirming it.

Sources

1. Vasireddi N, Hahamyan H, Salata MJ, Karns M, Calcei JG, Voos JE, Apostolakos JM. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025;21(4):485-495. DOI: 10.1177/15563316251355551. PMID: 40756949. pubmed.ncbi.nlm.nih.gov
2. Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med. 2021;27(4):8-13. PMID: 34324435. pubmed.ncbi.nlm.nih.gov
3. Lee E, Burgess K. Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med. 2025;31(5):20-24. PMID: 40131143. pubmed.ncbi.nlm.nih.gov
4. Esposito S, Deventer K, Goeman J, Van der Eycken J, Van Eenoo P. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal. 2012;4(9):733-738. DOI: 10.1002/dta.1402. PMID: 22962027. pubmed.ncbi.nlm.nih.gov
5. Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012;12(1):37-51. DOI: 10.1517/14712598.2012.634793. PMID: 22074294. pubmed.ncbi.nlm.nih.gov
6. Cox HD, Miller GD, Eichner D. Detection and in vitro metabolism of the confiscated peptides BPC 157 and MGF R23H. Drug Test Anal. 2017;9(10):1490-1498. DOI: 10.1002/dta.2152. PMID: 28035768. pubmed.ncbi.nlm.nih.gov
7. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Page updated 22 April 2026. fda.gov
8. U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee (agenda and materials). fda.gov
9. McDermott. Bulk-list bound? PCAC backs majority of peptides in two-day public meeting. 27 July 2026. mcdermottlaw.com
10. U.S. Food and Drug Administration, CDER. Warning Letter: Gram Peptides (MARCS-CMS 721806). 31 March 2026. fda.gov
11. Health Canada. Think twice before injecting peptides bought online: unauthorized products can seriously harm you. Public advisory, 9 April 2026. recalls-rappels.canada.ca
12. World Anti-Doping Agency. The 2026 Prohibited List (S0 Non-approved substances; S2 Peptide hormones, growth factors, related substances and mimetics). wada-ama.org

Editorial note: This article is for general information only and is not medical or legal advice. BPC-157 and TB-500 have not been evaluated by the FDA to diagnose, treat, cure or prevent any disease. Laws vary by location and change often, so verify the rules that apply where you are. Always talk to a licensed healthcare provider before use, especially if you are under 21, pregnant or nursing, taking medication, or managing a health condition.